Summit Therapeutics Inc. (SMMT) stock
SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.50−0.17 (-1.59%)
Close on Nov 18, 2026Market cap $8.38BP/E –Yield –
Summit Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Summit Therapeutics's price to sales ratio was 395.2× on Apr 28, 2023, against 4.6× a year earlier. Over the last 4 years it ranged from 0.4× to 395.2×, with a median of 1.9×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2023 | Apr 28, 2023 | 395.2× | +226.8 |
| 2022 | Nov 30, 2022 | 168.5× | +163.9 |
| 2021 | Dec 31, 2021 | 4.6× | +3.2 |
| 2020 | Dec 31, 2020 | 1.4× | +0.9 |
| 2019 | Dec 31, 2019 | 0.5× | – |
See a number that looks wrong?